Progressive supranuclear palsy (PSP) is a rare brain disease that causes problems with balance, eye movement, swallowing, and thinking. It belongs to a group of disorders driven by the abnormal buildup of a protein called tau inside brain cells, particularly in deep structures of the brain that control movement and coordination. Most people survive 5 to 7 years after symptoms begin, though some live longer. PSP is often mistaken for Parkinson’s disease early on, but it progresses differently and responds poorly to Parkinson’s medications.
What Happens in the Brain
In a healthy brain, tau protein helps stabilize the internal scaffolding of nerve cells. In PSP, a specific form of tau (called 4-repeat tau) accumulates in clumps inside neurons, as well as in the support cells that surround them. This buildup damages and eventually kills the affected cells.
The damage starts in a set of deep brain structures that sit below the cortex: the subthalamic nucleus, globus pallidus, and substantia nigra. These regions are central hubs for initiating and coordinating movement. As the disease advances, tau pathology spreads upward into the frontal and parietal cortex, then into the temporal and occipital cortex. The brainstem, which controls eye movements and swallowing, is heavily affected early on. This predictable pattern of spread explains why movement and eye problems appear first, while cognitive changes often develop later.
Early Signs and How They Progress
The hallmark early symptom is unexplained falls, particularly backward falls. Unlike Parkinson’s disease, where balance problems develop years into the illness, people with PSP typically begin falling within the first year. These falls are often unprovoked, meaning the person isn’t tripping over something or losing balance during a turn. They simply tip backward without the normal reflexive effort to catch themselves, frequently injuring the back of the head.
Stiffness in the trunk and neck is common early on, giving people an unusually upright or slightly arched posture. Walking becomes slower and more unsteady, and the gait tends to look different from the shuffling, forward-leaning walk typical of Parkinson’s. Speech may become slurred or slower, and the voice can take on a hoarse, strained quality.
Eye Movement Problems
The “supranuclear gaze palsy” in the disease’s name refers to a distinctive problem with voluntary eye movement. People gradually lose the ability to move their eyes up and down, particularly downward. This makes everyday tasks surprisingly difficult: reading, eating, navigating stairs, and making eye contact all become challenging. Many people compensate by moving their whole head instead of just their eyes when trying to look in a direction.
Other eye-related symptoms include slow eye movements, trouble controlling the eyelids (either involuntary closing or difficulty opening them), and reduced blinking. These problems tend to worsen as the disease progresses and can become one of the most disabling features.
Cognitive and Behavioral Changes
PSP is primarily a frontal lobe disorder, meaning it affects the part of the brain responsible for planning, decision-making, and impulse control. The cognitive changes look different from Alzheimer’s disease. Memory may be relatively preserved early on, but executive function declines: organizing tasks, switching between activities, and solving problems all become harder.
Apathy is one of the most common behavioral changes. People may lose motivation and initiative, withdrawing from activities they previously enjoyed. This can be mistaken for depression, which also occurs in PSP and should be monitored separately. Impulsivity is another characteristic feature. Some people eat too quickly or stuff food into their mouths before fully swallowing, which creates a choking risk on top of the swallowing difficulties the disease already causes.
Swallowing Difficulties and Their Risks
Dysphagia (difficulty swallowing) develops early in PSP compared to other neurodegenerative diseases, and it worsens rapidly. The muscles involved in chewing and moving food toward the throat are affected, not just the swallowing reflex itself. This leads to malnutrition, dehydration, and the most dangerous complication: aspiration pneumonia, where food or liquid enters the lungs and causes infection. Aspiration pneumonia is the leading cause of death in PSP.
Because swallowing function can decline quickly, regular assessments are important. These evaluations track how the swallow changes over time so that dietary modifications, such as thickened liquids or softer foods, can be introduced at the right stage. Early involvement of a speech-language pathologist helps identify risks before a serious aspiration event occurs.
How PSP Differs From Parkinson’s Disease
The overlap with Parkinson’s disease is the single biggest source of misdiagnosis. Both conditions cause slowness of movement and stiffness, but several features set PSP apart. Falls in PSP happen early and tend to be backward, while Parkinson’s-related falls usually occur later and tend to be forward. The postural stiffness in PSP affects the trunk and neck more than the limbs, and tremor, the classic Parkinson’s symptom, is uncommon in PSP.
The most telling difference is the response to levodopa, the standard Parkinson’s medication. In Parkinson’s disease, levodopa produces a clear, often dramatic improvement. In PSP, the response is much weaker. Studies show that roughly 26% to 44% of PSP patients get some benefit from levodopa, but the improvement is typically modest and no one experiences an excellent response. This poor medication response is itself a diagnostic clue.
How PSP Is Diagnosed
There is no single blood test or brain scan that confirms PSP. Diagnosis relies on the pattern of symptoms, their timing, and the exclusion of other conditions. Neurologists look for the combination of early falls, vertical eye movement problems, axial (trunk) stiffness, and a poor response to levodopa.
Brain MRI can support the diagnosis. As the disease progresses, the midbrain shrinks noticeably. On a sagittal MRI (a side-view slice), this shrinkage creates a shape sometimes called the “hummingbird sign,” where the midbrain resembles the beak of a hummingbird. This sign is helpful but not definitive. Its sensitivity varies widely, from about 46% to 92% depending on the radiologist reading the scan. Measuring the midbrain area directly, using a cutoff of 90 square millimeters, tends to be more reliable than a simple visual judgment call.
Treatment and Day-to-Day Management
No treatment currently slows or stops PSP. Management focuses on maintaining function, safety, and quality of life for as long as possible. A trial of levodopa is often attempted because a small proportion of patients do get modest relief from stiffness and slowness, but expectations should be realistic.
Physical therapy is central to care. Balance training, fall-prevention strategies, and gait exercises can help people stay mobile longer. Occupational therapy addresses daily tasks that become harder as coordination declines. For the eyelid-closing problems that some patients develop, injections of botulinum toxin into the muscles around the eyes can provide relief.
Speech therapy serves a dual role: maintaining communication as speech deteriorates and managing swallowing safety. As the disease advances, some people benefit from weighted utensils, modified food textures, and eventually feeding tubes when aspiration risk becomes too high. Depression, apathy, and sleep disturbances are treated individually as they arise, often with a combination of medication and psychological support.
Disease Course and Outlook
PSP progresses steadily. The classic form, called Richardson syndrome, tends to advance the fastest. Most people need a wheelchair within 3 to 5 years of symptom onset, and the typical disease duration from first symptoms to death is 5 to 7 years. The primary causes of death are aspiration pneumonia and complications from immobility, such as blood clots or infections.
Some people have variant forms of PSP that progress more slowly or initially resemble other conditions, like Parkinson’s disease or a primary language disorder. These variants can take longer to diagnose but ultimately follow a similar trajectory as tau pathology spreads through the brain. Regardless of the subtype, the deep brain structures along the pallido-nigro-luysian axis (the globus pallidus, substantia nigra, and subthalamic nucleus) are always heavily affected.